• Profile

Metabolic syndrome-related hyperuricemia is associated with a poorer prognosis in patients with colorectal cancer: A multicenter retrospective study

Cancer Management and Research Nov 26, 2021

Feng Q, Tang LJ, Luo DH, et al. - Metabolic syndrome (MetS)-related hyperuricemia holds prognostic importance on survival in colorectal cancer (CRC).

  • A correlation of hyperuricemia and MetS with the prognosis in malignant tumors has been reported.

  • A total of 1,271 patients who had undergone radical CRC resection were included and were preoperatively split into four groups: those with hyperuricemia alone (H), those with MetS alone (MS), those with MetS-related hyperuricemia (MSH), and those with neither condition (control [C] group).

  • Significant link between preoperative MetS and hyperuricemia was found.

  • In multivariate Cox regression analysis, MetS-related hyperuricemia (hazard ratio [HR] = 2.728) as well as MetS alone (HR = 1.631) were identified as independent predictors of death, whereas simple hyperuricemia was not.

  • Compared with the C group, the highest rate of tumor recurrence or metastasis was observed in the MSH group (HR = 5.103), followed by the MS (HR = 2.231) group.

  • There was a significant link of MetS with poor prognosis, with MetS-related hyperuricemia causing a significantly poorer prognosis.

  • In contrast, long-term prognosis remained unaffected by hyperuricemia alone.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen